Abstract:(Mol Ther. 22, 1333–1341; July 2014) The authors have discovered that the original article has errors in Figures 4, S1, and S2 that were introduced when a graduate student used the wrong shared image folder when putting together the figures. In the original Figure 4a, which shows expression of dystrophin-positive fibers in body-wide muscles, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4a now appears below. In the original Figure 4d, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure 4d now appears below. In the original Figure S1a, which shows expression of dystrophin-associated protein complex in quadriceps, control images for wild-type C57 and untreated mdx mice were repeatedly used instead of the right images corresponding to the mice used for this manuscript. The control images have been replaced and a corrected Figure S1a now appears below. In the original Figures S2a and S2b, a note should be added to the figure legend: the representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a, and the representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. The corrected legend appears below. These corrections do not change the conclusions of the paper. The authors apologize for the errors and any confusion they may have caused.Figure 4dFunctional and phenotypic correction in mdx mice following treatment with M12–PMO conjugates at a single dose of 75 mg/kg intravenouslyView Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure S1aFunctional evaluation of skeletal muscles following treatment with M12–PMO conjugates with 3 weekly injections at the dose of 25 mg/kg in mdx miceView Large Image Figure ViewerDownload Hi-res image Download (PPT) Figure S2. Histological and immunological measurement of potential toxicity in mdx mice treated with the M12–PMO conjugate with 3 weekly injections at 25 mg/kgThe representative control images for C57 and mdx mice shown in Figure 5b are repeated in Figure S2a. The representative control images for C57 and mdx mice shown in Figure 5a are repeated in Figure S2b. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide–Morpholino Conjugate in Dystrophin-Deficient mdx MiceGao et al.Molecular TherapyJuly, 2014In BriefAntisense oligonucleotide (AO)–mediated splice correction therapy for Duchenne muscular dystrophy has shown huge promise from recent phase 2b clinical trials, however high doses and costs are required and targeted delivery can lower both of these. We have previously demonstrated the feasibility of targeted delivery of AOs by conjugating a chimeric peptide, consisting of a muscle-specific peptide and a cell-penetrating peptide, to AOs in mdx mice. Although increased uptake in muscle was observed, the majority of peptide–AO conjugate was found in the liver. Full-Text PDF Open Archive

Unnatural Amino Acid‐Based Ionic Liquid Enables Oral Treatment of Nonsense Mutation Disease in Mice

Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient <i>mdx</i> Mice (vol 22, pg 1333, 2014)

Functional Rescue of Dystrophin-Deficient Mdx Mice by a Chimeric Peptide-PMO

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient Mdx Mice

Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy

An Octaguanidine-Morpholino Oligo Conjugate Improves Muscle Function Of Mdx Mice

L-arginine improves dystrophic phenotype in mdx mice

Small-molecule Activation of Lysosomal TRP Channels Ameliorates Duchenne Muscular Dystrophy in Mouse Models

MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice

Membrane Blebbing As an Assessment of Functional Rescue of Dysferlin-Deficient Human Myotubes Via Nonsense Suppression.

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy

The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders

Therapeutic Exon Skipping via a CRISPR-guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo

Novel AAV-mediated genome editing therapy improves health and survival in a mouse model of methylmalonic acidemia

Mdx mice dosed with antisense to CD49d and dystrophin exon skip morpholino; reduced force loss and affected gene expression pathways support ATL1102 combination therapy in DMD patients

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene